Multicenter, Open-Label, Safety, Tolerability, and Pharmacokinetic Study to Evaluate Single Ascending Doses and Fixed Doses of DVS SR Tablets in the Treatment of Child and Adolescent Outpatients With Major Depressive Disorder.
Latest Information Update: 03 Jan 2018
At a glance
- Drugs Desvenlafaxine (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer; Wyeth
- 11 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 03 Jul 2009 Planned end date (Jan 2010) added as reported by ClinicalTrials.gov.